navtemadlin
Small moleculeexperimental
Clinical trial activity
14 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
13
Phase 3
2
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03662126)
Timeline
Indications
Studied for
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 2/Phase 3
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Polycythemia Vera · Phase 2
- Primary Myelofibrosis · Phase 3
- Small Cell Lung Carcinoma · Phase 2
- Thrombocythemia, Essential · Phase 2
Mechanism of action
- p53-binding protein Mdm-2INHIBITOR
MDM2 inhibitor
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1- Mol. weight
- 568.56 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3125702 ↗
Also known as
- krt-232
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06479135 | Phase 3 | Jun 3, 2024 | Kartos Therapeutics, Inc. |
| NCT05797831 | Phase 2/Phase 3 (Phase 3) | Jul 17, 2023 | European Network for Gynaecological Oncological Trial, GOG Foundation, Inc., Kartos Therapeutics, Inc. |
| NCT05705466 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2023 | Kartos Therapeutics, Inc. |
| NCT05027867 | Phase 2 | Nov 30, 2021 | Kartos Therapeutics, Inc. |
| NCT04835584 | Phase 1/Phase 2 (Phase 2) | May 7, 2021 | Kartos Therapeutics, Inc. |
| NCT04878003 | Phase 2 | Apr 13, 2021 | Kartos Therapeutics, Inc. |
| NCT04669067 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2021 | Kartos Therapeutics, Inc., Telios Pharma, Inc. |
| NCT04485260 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Kartos Therapeutics, Inc. |
| NCT04502394 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Kartos Therapeutics, Inc. |
| NCT04640532 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2020 | Kartos Therapeutics, Inc., Telios Pharma, Inc. |
| NCT04113616 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2019 | Kartos Therapeutics, Inc. |
| NCT03787602 | Phase 2 | May 31, 2019 | Kartos Therapeutics, Inc. |
| NCT03669965 | Phase 2 | Oct 31, 2018 | Kartos Therapeutics, Inc. |
| NCT03662126 | Phase 2 | Sep 30, 2018 | Kartos Therapeutics, Inc. |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kartos Therapeutics, Inc. | For profit | 14 | 13 | 2 | 2018 |
| Telios Pharma, Inc. | For profit | 2 | 1 | 1 | 2020 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2023 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1